Jim Cramer on Eli Lilly: "It's Become Luckless"

Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated:

“How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t have a new use for Zepbound, the revolutionary GLP-1 drug, or announce the date for the pill version, the stock’s going to pull back to the $700s from its current $825 level. It can’t get out of its own way.”

Eli Lilly and Company (NYSE:LLY) develops prescription medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic diseases. A caller inquired about the stock during the October 21 episode, and Cramer responded:

“Here’s the problem with Lilly: they need to have something else to come out. They need something that’s big that the insurance companies will cover, for their drug, because right now, a lot of people just feel, you know what, this Ozempic thing, it’s played out. If you get something else, a new indication, that will ignite the stock.”

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.